Abstract
The article provides a scientifically grounded approach to pharmacotherapy of vascular and combined mental debility. The role and place of memantin, an uncompetitive low-affinity antagonist of NMDA-receptors in regulation of glutamate-dependent links of excitotoxicity in combined mental debilities. The effectiveness of memantin is proved for all stages and in various forms of mental debility, including combined mental debility, as well as compatibility with other drugs in combined therapy, a favourable safety profile and good drug tolerability.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
